DAFNA Capital Management’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.74M | Hold |
130,316
| – | – | 0.48% | 40 |
|
|
2025
Q1 | $1.33M | Hold |
130,316
| – | – | 0.38% | 47 |
|
|
2024
Q4 | $2.06M | Buy |
130,316
+56,562
| +77% | +$895K | 0.52% | 37 |
|
|
2024
Q3 | $4.28M | Buy |
73,754
+6,000
| +9% | +$348K | 1.01% | 26 |
|
|
2024
Q2 | $3.1M | Hold |
67,754
| – | – | 0.74% | 34 |
|
|
2024
Q1 | $4.49M | Sell |
67,754
-6,607
| -9% | -$437K | 1.02% | 29 |
|
|
2023
Q4 | $2.96M | Buy |
74,361
+8,400
| +13% | +$334K | 0.71% | 37 |
|
|
2023
Q3 | $2.1M | Buy |
65,961
+18,300
| +38% | +$583K | 0.65% | 39 |
|
|
2023
Q2 | $1.92M | Buy |
47,661
+28,300
| +146% | +$1.14M | 0.52% | 42 |
|
|
2023
Q1 | $827K | Sell |
19,361
-13,639
| -41% | -$582K | 0.25% | 50 |
|
|
2022
Q4 | $1.58M | Sell |
33,000
-6,000
| -15% | -$288K | 0.45% | 49 |
|
|
2022
Q3 | $1.47M | Hold |
39,000
| – | – | 0.39% | 49 |
|
|
2022
Q2 | $1.08M | Buy |
+39,000
| New | +$1.08M | 0.29% | 61 |
|